首页|逍遥丸对代谢相关脂肪性肝炎大鼠LXR-α/SREBP-1c通路的调节机制研究

逍遥丸对代谢相关脂肪性肝炎大鼠LXR-α/SREBP-1c通路的调节机制研究

扫码查看
目的 探讨逍遥丸对代谢相关脂肪性肝炎(MASH)大鼠的部分治疗机制,阐明中医"肝与大肠相通"理论对治疗MASH的指导意义。方法 选取成年雄性SD大鼠24只,将其随机分为空白组(Control组)8只,模型0组(Model 0组)16只。其中Control组给予普通饲料喂养,Model 0组给予高脂饮食喂养,40%四氯化碳背部皮下注射,同时给予饥饱失常和夹尾刺激,4周后,将Model 0组随机分为模型组(Model组)和逍遥丸组(XYW组),每组各8只。XYW组大鼠给予逍遥丸灌胃,其他两组给予生理盐水灌胃。给药4周后,分别测定大鼠肝功能和肝脂肪指标含量;苏木精-伊红(HE)染色观察肝组织病理变化;阿利新蓝-过碘酸雪夫(AB-PAS)染色观察肠道屏障受损情况;ELISA试剂盒测定大鼠肝匀浆中炎症因子水平;qRT-PCR 测定大鼠肝脏 LXR-α、SREBP-1c、Nrf2 及结肠 Claudin1、ZO-1、SREBP-1c、Nrf2 mRNA 的表达;Western blot检测大鼠肝脏LXR-α、SREBP-1c、Nrf2及结肠Claudin1、ZO-1、SREBP-1c、Nrf2的蛋白表达情况。结果 与Control组比较,Model 组大鼠血清 ALT、AST 以及肝匀浆 T-CHO、TG、LDL-C、IL-8、IL-17、TNF-α 水平升高(P<0。05),HDL-C、IL-10、TGF-β1 水平降低(P<0。01);Model 组大鼠肝组织 LXR-α、SREBP-1c mRNA 表达升高(P<0。001),Nrf2mRNA 表达降低(P<0。01),结肠组织 Claudin1、ZO-1、Nrf2 mRNA 的表达降低(P<0。01),SREBP-1c 的表达升高(P<0。01);Model组大鼠肝组织LXR-α、SREBP-1c蛋白水平升高(P<0。01),Nrf2降低(P<0。05),结肠组织中Claudin1、ZO-1、Nrf2蛋白水平降低(P<0。001),SREBP-1c升高(P<0。001)。结论 逍遥丸对MASH大鼠具有一定的治疗作用,其治疗机制可能与减轻炎症、氧化应激反应,抑制脂肪酸堆积有关;保护肠黏膜屏障免受损害可以有效减轻肝脏的损伤,"肝与大肠相通"理论对于MASH治疗具有一定的指导意义。
Exploration on the regulation mechanism of LXR-α/SREBP-1 c pathway in MASH rats based on the theory of"liver and large intestine communication"
Objective To explore the therapeutic mechanism of Xiaoyao pills on MASH rats,and to clarify the guiding significance of the theory of"connecting liver and large intestine"in TCM.Methods A total of 24 adult male SD rats were selected and randomly divided into Control group(8 rats)and Model group(16 rats).The Control group was fed with ordinary diet,and the Model 0 group was fed with high-fat diet,with subcutaneous injection of 40%carbon tetrachloride into the back,as well as with hunger and satiation disorder and tail-clip stimulation.4 weeks later,the Model 0 group was randomly divided into Model group and Xiaoyao pill group(XYW group),with 8 animals in each group.The rats in XYW group were given Xiaoyao pill and the other two groups were given normal sa-line.After 4 weeks of administration,the liver function and liver fat content of rats were measured respectively.Hematoxylin-eosin(HE)staining was used to observe the pathological changes of liver tissue.The damage of intestinal barrier was observed by Alcian blue-periodate Shev(AB-PAS)staining.The levels of inflammatory factors in rat liver homogenate were determined by ELISA kit.The mRNA expressions of LXR-α,SREBP-1c and Nrf2 in liver and Claudin1,ZO-1,SREBP-1c and Nrf2 in colon were determined by qRT-PCR.The protein expression of LXR-α,SREBP-1c and Nrf2 in liver and Claudin1,ZO-1,SREBP-1c and Nrf2 in colon were detected by Western blot.Results Compared with Control group,the levels of serum ALT,AST and liver homogenate T-CHO,TG,LDL-C,IL-8,IL-17 and TNF-α in Model group were increased(P<0.05),while the levels of HDL-C,IL-10 and TGF-β1 were decreased(P<0.01).In Model group,the mRNA expressions of LXR-α and SREBP-1c in liver tissue were increased(P<0.001),the mRNA expressions of Nrf2 were decreased(P<0.01),and the mrna expressions of Claudin1,ZO-1 and Nrf2 in colon tissue were decreased(P<0.01).The expression of SREBP-1c was increased(P<0.01).The protein levels of LXR-α and SREBP-1c in liver tissue of Model group were increased(P<0.01),while Nrf2 was decreased(P<0.05),the protein levels of Clau-din1,ZO-1 and Nrf2 in colon tissue were decreased(P<0.001),and SREBP-1 c was increased(P<0.001).Conclusion Xiaoyao Pill has a certain therapeutic effect on MASH rats,and its therapeutic mechanism may be related to reducing inflammation,oxidative stress and inhibiting fatty acid accumulation.Protecting the intestinal mucosal barrier from damage can effectively reduce the damage of the liver.The theory of"connecting the liver and the large intestine"has certain guiding significance for MASH treatment.

Metabolic related steatohepatitisXiaoyao pillLiver in the large intestineSterol regulatory element binding protein-1C(SREBP-1c)Nuclear factor E2-related factorNif2Liver X receptor α(LXR-α))

李梦琪、张馨月、张玉伟、孟雅楠、苗宇船

展开 >

山西中医药大学,山西晋中 030619

代谢相关脂肪性肝炎 逍遥丸 肝与大肠相通 肝X受体α 固醇调节元件结合蛋白-1c 核因子E2相关因子

2024

时珍国医国药
时珍国医国药杂志社

时珍国医国药

北大核心
影响因子:0.887
ISSN:1008-0805
年,卷(期):2024.35(13)